The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Linking poor cytogenetics and outcomes in MDS
Ibrahim Yakoub-Agha, MD, PhD, University of Lille, Lille, France, describes the impact of poor cytogenetics on survival rates post-allogeneic hematopoietic cell transplantation (allo-HCT) in patients with myelodysplastic syndromes (MDS). Previous studies on patients with acute myeloid leukemia (AML) have revealed that specific adverse cytogenetic features such as 17p and 5q abnormalities worsen outcomes post-transplant. However, no subset of complex karyotypes were identified in patients with MDS that significantly affected outcomes. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
